Cytokine and cytokine receptor single-nucleotide polymorphisms predict risk for non-small cell lung cancer among women

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 6, 2009, Pages 1829-1840

  Van Dyke, Alison L ^a,b   Cote, Michele L ^a,b   Wenzlaff, Angie S ^b   Chen, Wei ^a,b   Abrams, Judith ^a,b   Land, Susan ^a   Giroux, Craig N ^a,b   Schwartz, Ann G ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 15 RECEPTOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; INTERLEUKIN 7 RECEPTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER RISK; CAUCASIAN; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROTEIN FUNCTION; RACE DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

AFRICAN AMERICANS; CARCINOMA, NON-SMALL-CELL LUNG; CYTOKINES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, CYTOKINE; RISK FACTORS; SMOKING;

EID: 67449097647     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0962     Document Type: Article

References (61)

1. Ries LAG, Melbert D, Krapcho M, et al., editors. SEER cancer statistics review, 1975-2005, National Cancer Institute. Bethesda, MD, http://seer.cancer. gov/csr/1975-2005/, based on November 2007 SEER data submission, posted to the SEER Web site, 2008.
2. Edwards BK, Brown ML, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005;97:1407-1427
3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
4. Park JM, Choi JE, Chae MH, et al. Relationship between cyclooxygenase 8473T>C polymorphism and the risk of lung cancer: a case-control study. BMC Cancer 2006;6:70. (Pubitemid 43786478)
5. Hida T, Yatabe Y, Achiwa H, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998;58:3761-3764 (Pubitemid 28405625)
6. Fang HY, Lin TS, Lin JP, Wu YC, Chow KC, Wang LS. Cyclooxygenase-2 in human non-small cell lung cancer. Eur J Surg Oncol 2003;29:171-177 (Pubitemid 36367350)
7. Van Dyke AL, Cote ML, Prysak G, Claeys GB, Wenzlaff AS, Schwartz AG. Regular adult aspirin use decreases the risk of non-small cell lung cancer among women. Cancer Epidemiol Biomarkers Prev 2008;17:148-157 (Pubitemid 351196285)
8. Khuder SA, Herial NA, Mutgi AB, Federman DJ. Nonsteroidal antiinflammatory drug use and lung cancer: a metaanalysis. Chest 2005;127:748-754 (Pubitemid 40775501)
9. Schottenfeld D, Beebe-Dimmer J. Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin 2006;56:69-83.
10. Martin F, Santolaria F, Batista N, et al. Cytokine levels (IL-6 and IFN-γ), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 1999;11:80-86 (Pubitemid 29097356)
11. Matanic D, Beg-Zec Z, Stojanovic D, Matakoric N, Flego V, Milevoj-Ribic F. Cytokines in patients with lung cancer. Scand J Immunol 2003;57:173-178 (Pubitemid 36232885)
12. Brichory FM, Misek DE, Yim AM, et al. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci U S A 2001;98:9824-9829 (Pubitemid 32769388)
13. Tas F, Duranyildiz D, Argon A, et al. Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer. Med Oncol 2005;22:353-358 (Pubitemid 43780291)
14. Kaminska J, Kowalska M, Kotowicz B, et al. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathologic features and prognosis. M-CSF - an independent prognostic factor. Oncology 2006;70:115-125
15. McKeown DJ, Brown DJ, Kelly A, Wallace AM, McMillan DC. The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small cell lung cancer. Br J Cancer 2004;91:1993-1995 (Pubitemid 40128764)
16. Zienolddiny S, Ryberg D, Maggini V, Skaug V, Canzian F, Haugen A. Polymorphisms of the interleukin-1 β gene are associated with increased risk of non-small cell lung cancer. Int J Cancer 2004;109:353-356 (Pubitemid 38252762)
17. Asada M, Yasuda H, Ebihara S, et al. Interleukin-1β gene polymorphisms associated with risk of lung cancer in Japanese. Lung Cancer 2006;54:261-263 (Pubitemid 44764913)
18. Shih CM, Lee YL, Chiou HL, et al. The involvement of genetic polymorphism of IL-10 promoter in non-small cell lung cancer. Lung Cancer 2005;50:291-297 (Pubitemid 43300629)
19. Shih CM, Lee YL, Chiou HL, et al. Association of the TNF-α polymorphism with susceptibility to and severity of non-small cell lung cancer. Lung Cancer 2006;52:15-20. (Pubitemid 43340194)
20. Engels EA, Wu X, Gu J, Dong Q, Liu J, Spitz MR. Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer. Cancer Res 2007;67:6520-6527 (Pubitemid 47037538)
21. Ness RB, Haggerty CL, Harger G, Ferrell R. Differential distribution of allelic variants in cytokine genes among African Americans and White Americans. Am J Epidemiol 2004;160:1033-1038 (Pubitemid 39557455)
22. Hassan MI, Aschner Y, Manning CH, Xu J, Aschner JL. Racial differences in selected cytokine allelic and genotypic frequencies among healthy, pregnant women in North Carolina. Cytokine 2003;21:10-16 (Pubitemid 36369371)
23. Hoffmann SC, Stanley EM, Cox ED, et al. Ethnicity greatly influences cytokine gene polymorphism distribution. Am J Transplant 2002;2:560-567 (Pubitemid 36306876)
24. Cox ED, Hoffmann SC, DiMercurio BS, et al. Cytokine polymorphic analyses indicate ethnic differences in the allelic distribution of interleukin-2 and interleukin-6. Transplantation 2001;72:720-726 (Pubitemid 32802759)
25. Rady PL, Matalon R, Grady J, et al. Comprehensive analysis of genetic polymorphisms in the interleukin-10 promoter: implications for immune regulation in specific ethnic populations. Genet Test 2004;8:194-203. (Pubitemid 39096764)
26. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-387 (Pubitemid 26072233)
27. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995;57:289-300.
28. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a toolset for whole-genome association and population-based linkage analysis. Am J Hum Genet 2007;81:559-575 (Pubitemid 47330214)
29. French B, Lumley T, Monks SA, et al. Simple estimates of haplotype relative risks in case-control data. Genet Epidemiol 2006;30:485-494 (Pubitemid 44267165)
30. Ng PC, Heinkoff S. Predicting deleterious amino acid substitutions. Genome Res 2001;11:863-874 (Pubitemid 32447869)
31. Cosenza L, Gorgun G, Urbano A, Foss F. Interleukin-7 receptor expression and activation in nonhaematopoietic neoplastic cell lines. Cell Signal 2002;14:317-325 (Pubitemid 34164687)
32. Yang SC, Kim YW, Yoo CG, et al. IL-7 enhances the anti-tumor response in non-small cell lung cancer. Chest 2007;132:458S.
33. Standiford TJ, Strieter RM, Allen RM, Burdick MD, Kunkel SL. IL-7 up-regulates the expression of IL-8 from resting and stimulated human blood monocytes. J Immunol 1992;149:2035-2039
34. Mocellin S, Marincola FM, Young HA. Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol 2005;78:1043-1051 (Pubitemid 41572467)
35. Bernert H, Sekikawa K, Radcliffe RA, Iraqi F, You M, Malkinson AM. Tnfa and Il-10 deficiencies have contrasting effects on lung tumor susceptibility: gender-dependent modulation of IL-10 haploinsufficiency. Mol Carcinog 2003;38:117-123 (Pubitemid 37409822)
36. Sanlioglu AD, Aydin C, Bozcuk H, Terzioglu E, Sanlioglu S. Fundamental principals of tumor necrosis factor-α gene therapy approach and implications for patients with lung carcinoma. Lung Cancer 2004;44:199-211. (Pubitemid 38482053)
37. Kuschner WG, D'Alessandro A, Wong H, Blanc PD. Dose-dependent cigarette smoking-related inflammatory responses in healthy adults. Eur Respir J 1996;9:1989-1994 (Pubitemid 26333532)
38. Garey KW, Neuhauser MM, Robbins RA, Danziger LH, Rubinstein I. Markers of inflammation in exhaled breath condensate of young healthy smokers. Chest 2004;125:22-26 (Pubitemid 38114559)
39. McCrea KA, Ensor JE, Nall K, Bleecker ER, Hasday JD. Altered cytokine regulation in the lungs of cigarette smokers. Am J Respir Crit Care Med 1994;150:696-703. (Pubitemid 24291497)
40. Ryder MI, Saghizadeh M, Ding Y, Nguyen N, Soskolne A. Effects of tobacco smoke on the secretion of interleukin-1β, tumor necrosis factor-α, and transforming growth factor-β from peripheral blood mononuclear cells. Oral Microbiol Immunol 2002;17:331-336 (Pubitemid 36058766)
41. Mellick GD. TNF gene polymorphism and quantitative traits related to cardiovascular disease: getting to the heart of the matter. Eur J Human Genet 2007;15:609-611
42. Kobayashi H, Dubois S, Sato N, et al. Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood 2005;105:721-727 (Pubitemid 40070758)
43. Takeuchi E, Yanagawa H, Suzuki Y, Shinkawa K, Bando H, Sone S. Interleukin (IL-)15 has less activity than IL-2 to promote type 2 cytokine predominance in tumour-associated mononuclear cells from lung cancer patients. Cytokine 2001;13:119-123 (Pubitemid 32579319)
44. Chapoval AI, Fuller JA, Kremlev SG, Kamdar SJ, Evans R. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells. J Immunol 1998;161:6977-6984 (Pubitemid 28562246)
45. Mukhopadhyaya S, Hoidal JR, Mukherjee TK. Role of TNFα in pulmonary pathophysiology. Respir Res 2006;7:125-133 (Pubitemid 44637860)
46. Chung KF. Cytokines in chronic obstructive pulmonary disease. Eur Respir J 2001;18:50-9s. (Pubitemid 34760609)
47. Gan WQ, Man SFP, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004;59:574-580 (Pubitemid 38901515)
48. Antoniu SA, Mihaltan F, Ulmeanu R. Anti-TNF-α therapies in chronic obstructive pulmonary diseases. Expert Opin Investig Drugs 2008;17:1203-1211
49. Highuchi T, Seki N, Kamizono S, et al. Polymorphism of the 5′-flanking region of the human tumor necrosis factor (TNF)-α gene in Japanese. Tissue Antigens 1998;51:605-612 (Pubitemid 28306464)
50. Skoog T, van't Hooft FM, Kallin B, et al. A common function polymorphism (C→A substitution at position -863) in the promoter region of the tumour necrosis factor-α (TNF-α) gene associated with reduced circulating levels of TNF-α. Hum Mol Genet 1999;8:1443-1449
51. Sharma S, Sharma A, Kumar S, Sharma SK, Ghosh B. Association of the TNF haplotypes with asthma, serum IgE levels, and correlation with serum TNF-α levels. Am J Respir Cell Mol Biol 2006;35:488-495 (Pubitemid 44477649)
52. Qi Y, Bar-Joseph Z, Klein-Seetheraman J. Evaluation of different biological data and computational classification methods for use in protein interaction prediction. Proteins 2006;63:490-500.
53. Lee JW, Lee JB, Park M, Song SH. An extensive comparison of recent classification tools applied to microarray data. Comput Stat Data Anal 2005;48:869-885
54. Dudoit S, Fridlyand J, Speed TP. Comparison of discrimination methods for the classification of tumors using gene expression data. J Am Stat Assoc 2002;97:77-87.
55. Yuan A, Chen JJ, Yao PL, Yang PC. The role of interleukin-8 in cancer cells and microenvironment interaction. Front Biosci 2005;10:853-865
56. Kim K, Fisher MJ, Xu SQ, El-Deiry WS. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 2000;6:335-346 (Pubitemid 30111448)
57. Spierings DCJ, de Vries EGE, Timens W, Groen HJM, Boezen HM, de Jong S. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res 2003;9:3397-3405 (Pubitemid 37082735)
58. Takizawa H, Tanaka M, Takami K, et al. Increased expression of inflammatory mediators in small-airway epithelium from tobacco smokers. Am J Physiol Lung Cell Mol Physiol 2000;278:L906-13. (Pubitemid 30351045)
59. Martin D, Galisteo R, Gutkind JS. CXCL8/IL8 stimulates VEGF expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFκB through the CBM (CARMA3/BCL10/MATL1) complex. J Biol Chem 2009;48:6038-6042
60. Boost KA, Saidk CD, Bachmann M, Zwissler B, Pfeilschifter J, Muhl H. IFN-γ impairs release of IL-8 by IL-1β-stimulated A549 lung carcinoma cells. BMC Cancer 2008;8:265-272
61. Zeng W, Miyazato A, Chen G, Kajigaya S, Young NS, Maciejewski JP. Interferon-γ-induced gene expression in CD34 cells: identification of pathologic cytokine-specific signature profiles. Blood 2006;107:167-175 (Pubitemid 43053539)